Leon Nanodrugs key facts
as of Oct 2026- Developer of drugs through nanoscience designed to offer patient outcomes.
- Leon Nanodrugs is valued at approximately $71.0M as of Oct 2026 (last reported valuation).
- It has raised $20.5M; the latest was Later Stage VC in Feb 2026.
- Notable investors include LBBW Venture Capital, Albany Capital (Australia), Albany Private Equity Holding, Bayerische Beteiligungsgesellschaft, CB one Holding — 11 tracked in total.
- Status: Privately Held (backing).
Leon Nanodrugs's last reported valuation, Jul 2015. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Leon Nanodrugs: the Monday email on marks, rounds and moves
Leon Nanodrugs funding rounds
No funding rounds for Leon Nanodrugs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Leon Nanodrugs
11+Leon Nanodrugs valuation
Leon Nanodrugs's last reported valuation was $71 million in Jul 2015. No priced round, secondary trade or fund mark has surfaced since.
Leon Nanodrugs investors
11 investors are on record for Leon Nanodrugs, including LBBW Venture Capital, Albany Capital (Australia), Albany Private Equity Holding and Bayerische Beteiligungsgesellschaft.
About Leon Nanodrugs
Developer of drugs through nanoscience designed to offer patient outcomes. The company's drugs specialize in improving the bioavailability of poorly water-soluble medicine by using their proprietary technology to create either polymeric or crystalline nanoparticles, enabling medical professionals to get nano-formulated drugs with meaningful differentiation and added benefits.
- Sector
- Healthcare
- HQ
- Planegg, Germany
- Founded
- 2010
- Employees
- 14
- Website
- leon-nanodrugs.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.